130 related articles for article (PubMed ID: 31231460)
1. Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study.
Guadagni S; Fiorentini G; Mambrini A; Masedu F; Valenti M; Mackay AR; Sarti D; Ricevuto E; Clementi M; Catarci M; Lazzarin G; Bruera G
Oncotarget; 2019 Jun; 10(39):1-13. PubMed ID: 31231460
[TBL] [Abstract][Full Text] [Related]
2. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.
Guadagni S; Fiorentini G; De Simone M; Masedu F; Zoras O; Mackay AR; Sarti D; Papasotiriou I; Apostolou P; Catarci M; Clementi M; Ricevuto E; Bruera G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):205-219. PubMed ID: 31620896
[TBL] [Abstract][Full Text] [Related]
3. Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Guadagni S; Clementi M; Bencivenga M; Kusamura S; Fiorentini C; Masedu F
Updates Surg; 2018 Dec; 70(4):441-447. PubMed ID: 30191532
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.
Guadagni S; Fiorentini G; Palumbo P; Masedu F; Ricevuto E; Bruera G; Deraco M; Kusamura S; Sarti D; Fiorentini C; Gailhofer S; Clementi M
Minerva Chir; 2019 Aug; 74(4):304-312. PubMed ID: 31062943
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer.
Guadagni S; Fiorentini G; Palumbo G; Valenti M; Russo F; Cantore M; Deraco M; Vaglini M; Amicucci G
Arch Surg; 2001 Jan; 136(1):105-12. PubMed ID: 11146790
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.
Guadagni S; Fiorentini G; Clementi M; Palumbo P; Mambrini A; Masedu F
Updates Surg; 2017 Sep; 69(3):403-410. PubMed ID: 28791628
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
8. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
van Ijken MG; van Etten B; Guetens G; de Bruijn EA; Ten Hagen TL; Wiggers T; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):897-904. PubMed ID: 16084053
[TBL] [Abstract][Full Text] [Related]
9. Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice.
Bruera G; Pepe F; Malapelle U; Di Staso M; Dal Mas A; Di Giacomo D; Scerbo G; Santilli M; Ciacco E; Simmaco M; Troncone G; Coco C; Giuliante F; Ricevuto E
Ann Transl Med; 2021 Jun; 9(12):1027. PubMed ID: 34277827
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.
Guadagni S; Aigner KR; Palumbo G; Cantore M; Fiorentini G; Pozone T; Deraco M; Clerico M; Chaudhuri PK
J Clin Pharmacol; 1998 Oct; 38(10):936-44. PubMed ID: 9807975
[TBL] [Abstract][Full Text] [Related]
12. Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs.
van IJken MG; de Bruijn EA; ten Hagen TL; de Boeck G; van Eijck CH; Eggermont AM
Eur J Surg Oncol; 2004 Aug; 30(6):699-707. PubMed ID: 15256247
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
Guadagni S; Santinami M; Patuzzo R; Pilati PL; Miotto D; Deraco M; Rossi CR; Fiorentini G; Di Filippo F; Valenti M; Amicucci G
Melanoma Res; 2003 Feb; 13(1):51-8. PubMed ID: 12569285
[TBL] [Abstract][Full Text] [Related]
14. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
[TBL] [Abstract][Full Text] [Related]
16. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Wanebo HJ; DiSiena M; Begossi G; Belliveau J; Gustafson E
Ann Surg Oncol; 2008 Apr; 15(4):1107-16. PubMed ID: 18157578
[TBL] [Abstract][Full Text] [Related]
17. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases.
Fiorentini G; Aliberti C; Sarti D; Coschiera P; Tilli M; Mulazzani L; Giordani P; Graziano F; Gonzalez AM; Marcos RG; Mugnoz FG; Cantore M; Ricci S; Catalano V; Mambrini A
World J Gastrointest Oncol; 2015 Jun; 7(6):47-54. PubMed ID: 26090075
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.
Pohlen U; Rieger H; Kunick-Pohlen S; Berger G; Buhr HJ
Anticancer Res; 2007; 27(1B):667-74. PubMed ID: 17348458
[TBL] [Abstract][Full Text] [Related]
19. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC.
Prager G; Köhne CH; O'Connor JM; Rivera F; Santini D; Wasan H; Phelip JM
Curr Oncol; 2021 Jun; 28(3):2097-2106. PubMed ID: 34199694
[TBL] [Abstract][Full Text] [Related]
20. 5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
Pernot S; Velut G; Kourie RH; Amouyal G; Sapoval M; Pointet AL; Landi B; Zaimi Y; Lepère C; Pellerin O; Taieb J
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):255-260. PubMed ID: 29233520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
